Manulife (Manufacturers Life Insurance)’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-39,386
| Closed | -$120K | – | 3019 |
|
|
2024
Q4 | $120K | Sell |
39,386
-1,299
| -3% | -$5.66K | ﹤0.01% | 2782 |
|
|
2024
Q3 | $211K | Sell |
40,685
-1,611
| -4% | -$8.01K | ﹤0.01% | 2645 |
|
|
2024
Q2 | $109K | Buy |
42,296
+9,601
| +29% | +$32.8K | ﹤0.01% | 2802 |
|
|
2024
Q1 | $161K | Sell |
32,695
-7,525
| -19% | -$44.5K | ﹤0.01% | 2671 |
|
|
2023
Q4 | $354K | Sell |
40,220
-1,352
| -3% | -$11.1K | ﹤0.01% | 2329 |
|
|
2023
Q3 | $477K | Buy |
41,572
+8,260
| +25% | +$159K | ﹤0.01% | 2164 |
|
|
2023
Q2 | $843K | Buy |
33,312
+1,635
| +5% | +$50.9K | ﹤0.01% | 1750 |
|
|
2023
Q1 | $1.02M | Buy |
31,677
+1,079
| +4% | +$33.6K | ﹤0.01% | 1626 |
|
|
2022
Q4 | $565K | Buy |
30,598
+3,161
| +12% | +$72.3K | ﹤0.01% | 1906 |
|
|
2022
Q3 | $741K | Sell |
27,437
-493
| -2% | -$10K | ﹤0.01% | 1743 |
|
|
2022
Q2 | $386K | Sell |
27,930
-1,133
| -4% | -$17.4K | ﹤0.01% | 2218 |
|
|
2022
Q1 | $567K | Sell |
29,063
-7,916
| -21% | -$120K | ﹤0.01% | 2128 |
|
|
2021
Q4 | $603 | Buy |
36,979
+511
| +1% | +$8.52K | ﹤0.01% | 2152 |
|
|
2021
Q3 | $1.02M | Sell |
36,468
-3,007
| -8% | -$85.8K | ﹤0.01% | 1824 |
|
|
2021
Q2 | $1.17M | Buy |
39,475
+3,671
| +10% | +$106K | ﹤0.01% | 1900 |
|
|
2021
Q1 | $1M | Sell |
35,804
-2,029
| -5% | -$56.1K | ﹤0.01% | 1880 |
|
|
2020
Q4 | $1.07M | Buy |
37,833
+2,275
| +6% | +$58.9K | ﹤0.01% | 1775 |
|
|
2020
Q3 | $894K | Buy |
35,558
+1,852
| +5% | +$48.6K | ﹤0.01% | 1718 |
|
|
2020
Q2 | $862K | Buy |
33,706
+2,583
| +8% | +$51K | ﹤0.01% | 1687 |
|
|
2020
Q1 | $461K | Buy |
31,123
+4,463
| +17% | +$92.3K | ﹤0.01% | 1879 |
|
|
2019
Q4 | $433K | Sell |
26,660
-1,585
| -6% | -$24.6K | ﹤0.01% | 2133 |
|
|
2019
Q3 | $389K | Sell |
28,245
-23
| -0.1% | -$281 | ﹤0.01% | 2163 |
|
|
2019
Q2 | $367K | Buy |
28,268
+2,691
| +11% | +$33.9K | ﹤0.01% | 2237 |
|
|
2019
Q1 | $403K | Buy |
25,577
+4,879
| +24% | +$84.6K | ﹤0.01% | 2180 |
|
|
2018
Q4 | $417K | Sell |
20,698
-1,493
| -7% | -$32.9K | ﹤0.01% | 2070 |
|
|
2018
Q3 | $552K | Sell |
22,191
-2,578
| -10% | -$70.1K | ﹤0.01% | 2210 |
|
|
2018
Q2 | $680K | Buy |
24,769
+4,323
| +21% | +$130K | ﹤0.01% | 2150 |
|
|
2018
Q1 | $630K | Buy |
20,446
+2,274
| +13% | +$73.2K | ﹤0.01% | 2164 |
|
|
2017
Q4 | $650K | Buy |
18,172
+234
| +1% | +$6.72K | ﹤0.01% | 2142 |
|
|
2017
Q3 | $495K | Sell |
17,938
-366
| -2% | -$8.87K | ﹤0.01% | 2283 |
|
|
2017
Q2 | $483K | Buy |
18,304
+1,275
| +7% | +$28.4K | ﹤0.01% | 2317 |
|
|
2017
Q1 | $354K | Buy |
17,029
+2,021
| +13% | +$41.5K | ﹤0.01% | 2424 |
|
|
2016
Q4 | $311K | Buy |
15,008
+340
| +2% | +$5.69K | ﹤0.01% | 2448 |
|
|
2016
Q3 | $238K | Sell |
14,668
-252
| -2% | -$3.66K | ﹤0.01% | 2642 |
|
|
2016
Q2 | $203K | Buy |
14,920
+2,500
| +20% | +$44.2K | ﹤0.01% | 2694 |
|
|
2016
Q1 | $218K | Buy |
12,420
+1,688
| +16% | +$34.4K | ﹤0.01% | 2538 |
|
|
2015
Q4 | $366 | Buy |
10,732
+210
| +2% | +$7.28K | ﹤0.01% | 2225 |
|
|
2015
Q3 | $313 | Buy |
10,522
+140
| +1% | +$4.25K | ﹤0.01% | 2303 |
|
|
2015
Q2 | $332 | Buy |
10,382
+3,671
| +55% | +$94.4K | ﹤0.01% | 2425 |
|
|
2015
Q1 | $140 | Buy |
6,711
+163
| +2% | +$2.82K | ﹤0.01% | 2994 |
|
|
2014
Q4 | $111 | Buy |
6,548
+902
| +16% | +$15.8K | ﹤0.01% | 3034 |
|
|
2014
Q3 | $109 | Buy |
5,646
+1,200
| +27% | +$31.3K | ﹤0.01% | 3054 |
|
|
2014
Q2 | $151K | Buy |
+4,446
| New | +$139K | ﹤0.01% | 2930 |
|
Other funds holding RVNC
Manulife (Manufacturers Life Insurance)'s RVNC Position: Q1 2025 in Review
Manulife (Manufacturers Life Insurance) sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 39,386 shares — an estimated $120K sold.
Manulife (Manufacturers Life Insurance) first reported a position in RVNC in Q2 2014 and held it in 43 quarters. The position peaked at $1.17M in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Manulife (Manufacturers Life Insurance) reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Manulife (Manufacturers Life Insurance) sold 39,386 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $120K.
- Manulife (Manufacturers Life Insurance) first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 43 quarters.
- Manulife (Manufacturers Life Insurance)'s Revance Therapeutics, Inc. position peaked at $1.17M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2025, filed 15 May 2025.